Last reviewed · How we verify

Travanti Pharma Inc. — Portfolio Competitive Intelligence Brief

Travanti Pharma Inc. pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Bristol-Myers Squibb · 1 shared drug class
  2. ClinAmygate · 1 shared drug class
  3. F. Johannes Plate · 1 shared drug class
  4. First Affiliated Hospital of Wenzhou Medical University · 1 shared drug class
  5. First Affiliated Hospital of Zhejiang University · 1 shared drug class
  6. GlaxoSmithKline · 1 shared drug class
  7. Guangdong Hengrui Pharmaceutical Co., Ltd · 1 shared drug class
  8. Ain Shams University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Travanti Pharma Inc.:

Cite this brief

Drug Landscape (2026). Travanti Pharma Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/travanti-pharma-inc. Accessed 2026-05-16.

Related